Journal of Psychopharmacology
August 5, 2020
Will Lawn, J. P. Hill, Chandni Hindocha et al.
23 citations
A single 600 mg oral dose of cannabidiol did not alter brain activity related to anticipating or receiving rewards in healthy adults. Using functional magnetic resonance imaging during a monetary incentive delay task, the expected reward-related brain regions—including the insula, caudate, nucleus accumbens, anterior cingulate, and orbitofrontal cortex—were activated, but no difference was observed between cannabidiol and placebo. Bayesian analyses confirmed that activity in these regions was similar under both conditions, and behavioral measures of motivation for reward also showed no significant difference. The findings suggest that acute cannabidiol does not affect the neural correlates of reward anticipation or feedback in healthy individuals.
Translational psychiatry
July 25, 2024
Ariela S Buxbaum Grice, Laura Sloofman, Tess Levy et al.
3 citations
A single low-dose intravenous ketamine infusion (0.5 mg/kg) triggers immediate and profound changes in gene expression in the blood of individuals with ADNP syndrome, a rare neurodevelopmental disorder. These alterations include upregulation of immune and inflammatory processes and downregulation of RNA processing and metabolism, with specific enrichment in monocyte-related expression patterns. The changes are transient, returning to baseline within 24 hours to one week. The findings clarify ketamine's molecular effects and support further research into its therapeutic targets for ADNP syndrome and potentially autism spectrum disorder.
medRxiv Preprint Server
January 29, 2024
Ariela S. Buxbaum Grice, Laura Sloofman, Tess Levy et al.
1 citation
preprint
A single low-dose intravenous ketamine infusion (0.5 mg/kg) triggers immediate and profound changes in gene expression in the blood of 10 individuals with ADNP syndrome, a rare neurodevelopmental disorder causing intellectual disability, developmental delay, and autism spectrum disorder. The alterations are enriched in monocyte-related patterns, with up-regulation of immune and inflammatory processes and down-regulation of RNA processing and metabolism. These changes are transient, returning to baseline within 24 hours to one week after treatment. The findings clarify ketamine's molecular effects and may guide therapeutic development for ADNP syndrome and possibly autism spectrum disorder.